Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study

BACKGROUND Atrial fibrillation is an important cause of morbidity and mortality worldwide, but scant data are available for long-term outcomes in individuals outside North America or Europe, especially in primary care settings. METHODS We did a cohort study using a prospective registry of patients in 47 countries who presented to a hospital emergency department with atrial fibrillation or atrial flutter as a primary or secondary diagnosis. 15 400 individuals were enrolled to determine the occurrence of death and strokes (the primary outcomes) in this cohort over eight geographical regions (North America, western Europe, and Australia; South America; eastern Europe; the Middle East and Mediterranean crescent; sub-Saharan Africa; India; China; and southeast Asia) 1 year after attending the emergency department. Patients from North America, western Europe, and Australia were used as the reference population, and compared with patients from the other seven regions FINDINGS Between Dec 24, 2007, and Oct 21, 2011, we enrolled 15 400 individuals to the registry. Follow-up was complete for 15 361 (99·7%), of whom 1758 (11%) died within 1 year. Fewer deaths occurred among patients presenting to the emergency department with a primary diagnosis of atrial fibrillation compared with patients who had atrial fibrillation as a secondary diagnosis (377 [6%] of 6825 patients vs 1381 [16%] of 8536, p<0·0001). Twice as many patients had died by 1 year in South America (192 [17%] of 1132) and Africa (225 [20%] of 1137) compared with North America, western Europe, and Australia (366 [10%] of 3800, p<0·0001). Heart failure was the most common cause of death (519 [30%] of 1758); stroke caused 148 (8%) deaths. 604 (4%) of 15361 patients had had a stroke by 1 year; 170 (3%) of 6825 for whom atrial fibrillation was a primary diagnosis and 434 (5%) of 8536 for whom it was a secondary diagnosis (p<0·0001). The highest number of strokes occurred in patients in Africa (89 [8%] of 1137), China (143 [7%] of 2023), and southeast Asia (88 [7%] of 1331) and the lowest occurred in India (20 [<1%] of 2536). 94 (3%) of 3800 patients in North America, western Europe, and Australia had a stroke. INTERPRETATION Marked unexplained inter-regional variations in the occurrence of stroke and mortality suggest that factors other than clinical variables might be important. Prevention of death from heart failure should be a major priority in the treatment of atrial fibrillation. FUNDING Boehringer Ingelheim.

[1]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[2]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.

[3]  Phalla Ou,et al.  Prevalence of rheumatic heart disease detected by echocardiographic screening. , 2007, The New England journal of medicine.

[4]  F. McAlister,et al.  Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.

[5]  C. Camargo,et al.  Increasing US emergency department visit rates and subsequent hospital admissions for atrial fibrillation from 1993 to 2004. , 2008, Annals of emergency medicine.

[6]  Basile Chaix,et al.  A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena , 2006, Journal of Epidemiology and Community Health.

[7]  I. V. Van Gelder,et al.  Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry , 2014, Circulation.

[8]  G. Lip,et al.  Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. , 2015, European heart journal.

[9]  L. Williams,et al.  Validating the Questionnaire for Verifying Stroke-Free Status (QVSFS) by Neurological History and Examination , 2001, Stroke.

[10]  G. Lip,et al.  Added Predictive Ability of the CHA2DS2VASc Risk Score for Stroke and Death in Patients With Atrial Fibrillation: The Prospective Danish Diet, Cancer, and Health Cohort Study , 2012, Circulation. Cardiovascular quality and outcomes.

[11]  Martin McKee,et al.  Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. , 2013, JAMA.

[12]  Brown Wv Framingham Heart Study. , 2011, Journal of clinical lipidology.

[13]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[14]  M. Zubaid,et al.  Gulf Survey of Atrial Fibrillation Events (Gulf SAFE): Design and Baseline Characteristics of Patients With Atrial Fibrillation in the Arab Middle East , 2011, Circulation. Cardiovascular quality and outcomes.

[15]  J. Healey,et al.  Stroke prevention in patients with atrial fibrillation: the diagnosis and management of hypertension by specialists. , 2006, The Canadian journal of cardiology.

[16]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[17]  G. Boriani,et al.  'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[18]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[19]  É. Marijon,et al.  Rheumatic heart disease , 2012, The Lancet.

[20]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.

[21]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.

[22]  G. Breithardt,et al.  The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. , 2010, The American journal of cardiology.

[23]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[25]  Silvia G Priori,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit , 2006, Journal of the American College of Cardiology.

[26]  F A Mathewson,et al.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. , 1995, The American journal of medicine.

[27]  L. Chambers,et al.  Improving cardiovascular health at population level: 39 community cluster randomised trial of Cardiovascular Health Awareness Program (CHAP) , 2011, BMJ : British Medical Journal.

[28]  T. Kural,et al.  Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. , 1996, The American journal of cardiology.

[29]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[30]  Dietrich Andresen,et al.  Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.

[31]  P. Armstrong,et al.  Impact of specialist follow-up in outpatients with congestive heart failure , 2005, Canadian Medical Association Journal.

[32]  G. Lip,et al.  Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature , 2012, Circulation.

[33]  G. Lip,et al.  Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.

[34]  J. Tu,et al.  Temporal trends in medication use and outcomes in atrial fibrillation. , 2013, The Canadian journal of cardiology.

[35]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[36]  P. Wolf,et al.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke , 1978, Neurology.

[37]  S. Raudenbush,et al.  Predicting Risk-Adjusted Mortality for CABG Surgery: Logistic Versus Hierarchical Logistic Models , 2005, Medical care.

[38]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[39]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[40]  Kenneth A Ellenbogen,et al.  2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Heart rhythm.

[41]  C. Atzema,et al.  Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department: a description of their characteristics and outcomes. , 2013, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[42]  M. Zubaid,et al.  Management and 1-Year Outcomes of Patients With Atrial Fibrillation in the Middle East , 2015, Angiology.

[43]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[44]  P. Urban,et al.  Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.